A combination of lapatinib with capecitabine has been proved to be effective in the treatment of HER2 overexpression breast cancer, which progresses post trastuzumab treatment.[4] On the other hand, pyrotinib is an irreversible pan ERBB receptor tyrosine kinase inhibitor, which simultaneously targets EGFR and/or HER2 and/or HER4.[5]. The gene discussed is ERBB2; the disease is breast carcinoma.